Omnicell, Inc. (NASDAQ:OMCL) Receives $50.67 Consensus PT from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been given an average recommendation of “Hold” by the six brokerages that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $45.83.

Several equities analysts have recently issued reports on OMCL shares. Wells Fargo & Company decreased their price objective on Omnicell from $38.00 to $31.00 and set an “equal weight” rating for the company in a report on Wednesday. Benchmark decreased their price target on Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday. JPMorgan Chase & Co. cut their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Finally, StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, May 3rd.

Institutional Investors Weigh In On Omnicell

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Shaker Investments LLC OH purchased a new stake in shares of Omnicell during the fourth quarter worth about $550,000. Empowered Funds LLC purchased a new stake in Omnicell during the 4th quarter worth approximately $388,000. Exchange Traded Concepts LLC raised its holdings in shares of Omnicell by 6.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company’s stock valued at $14,232,000 after acquiring an additional 20,031 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Omnicell by 56.5% in the fourth quarter. SG Americas Securities LLC now owns 39,359 shares of the company’s stock valued at $1,752,000 after acquiring an additional 14,202 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new stake in shares of Omnicell in the fourth quarter worth approximately $201,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $25.88 on Friday. Omnicell has a 52 week low of $22.66 and a 52 week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.21 billion, a P/E ratio of 95.86, a P/E/G ratio of 7.53 and a beta of 0.78. The business’s 50 day moving average price is $32.28 and its 200 day moving average price is $39.96.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.03 earnings per share. On average, sell-side analysts expect that Omnicell will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.